AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca, in collaboration with Parexel International, has completed a clinical study titled ‘An Open-label, Fixed Sequence Study in Healthy Participants to Assess the Effect of Multiple Doses of AZD2389 on the Pharmacokinetics of Midazolam, Caffeine, and Bupropion.’ The study aimed to evaluate how repeated doses of AZD2389 influence the pharmacokinetics of these drugs in healthy individuals, which is crucial for understanding potential drug interactions and optimizing therapeutic regimens.
The intervention involved administering AZD2389, a drug under investigation, alongside midazolam, caffeine, and bupropion. AZD2389 was given over several days, with specific combinations on designated days to observe interaction effects.
This Phase 1 study was interventional with a single-group assignment. It was open-label, meaning no masking was involved, and focused on treatment purposes, providing clear insights into drug interactions.
The study began on May 8, 2025, and was completed with the last update on July 23, 2025. These dates are significant as they mark the study’s timeline and progress, indicating a swift completion and update cycle.
From a market perspective, the completion of this study could positively influence AstraZeneca’s stock performance by showcasing their commitment to advancing drug safety and efficacy. It may also enhance investor confidence, given the collaboration with Parexel, a reputable clinical research organization. Competitors might take note of these developments as AstraZeneca continues to innovate in pharmacokinetics research.
The study is completed, with further details available on the ClinicalTrials portal.